OGN Stock — Organon & Co.

Organon & Co. (OGN)

Updated October 16, 2026.

OGN is a Stock. its distribution rate is 0.58%, its trailing-12-month yield is 0.58%. Dividend Vision Distribution Safety Score™ is 9/100 (High risk). Total return is -49.1% over the past 5.4 years, 146.3 points behind SPY at 97.2%.

Organon & Co. is a pharmaceutical company that develops and delivers women's health solutions through prescription therapies and medical devices globally, with additional product portfolios in biosimilars, cholesterol-modifying and cardiovascular medicines, respiratory treatments, dermatology, bone health, and pain management. The company distributes a modest current dividend on a quarterly basis. The stock may appeal to income investors seeking exposure to the pharmaceutical sector, though the dividend yield is relatively low.

OGN performance versus SPY

Price and return data through 2026-10-16.

Total return is -49.1% over the past 5.4 years, 146.3 points behind SPY at 97.2%. Over the past year its total return — price change plus distributions reinvested — is 47.9%. Its deepest 1-year drawdown was 41.5%.

OGN key facts

Distribution Safety Score™

9 · High risk

Safety-Adjusted Yield

0.05%

Asset type

Stock

Asset class

Equity

Inception date

05/14/2021

Distribution rate

0.58%

Distribution frequency

Quarterly

Trailing yield

0.58%

5-year average yield

2.48

Last close

$13.76 (as of 2026-10-16)

Market cap

$3,613,505,798

Average volume

2646609.0

Dividend

$0.02

Ex-dividend date

08/14/2026

Payment date

09/10/2026

Beta

1.542

Payout ratio

2.5%

P/E ratio

17.64

Forward P/E

5.0891

EPS

$0.78

How Dividend Vision calculates yield and returns

Distribution rate (0.58%) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield (0.58%) is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

OGN risks and drawbacks

OGN's current distribution rate is moderate, not a high-yield payout — the strategy is dividend quality more than maximum income. Payments are quarterly, so cash flow is lumpy versus a monthly fund. Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 41.5%.

Who may consider OGN — and who may not

It is a weaker fit for investors who need monthly cash flow (OGN pays quarterly); investors hunting double-digit covered-call yields; investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on OGN

• All tickers starting with O

Tagged: Pharmaceutical, Dividend.

Frequently asked questions